Golledge, Jonathan (2023) Can a genetic mutation associated with glycosuria teach us about the action of sodium-glucose cotransporter-2 inhibitors? Cardiovascular Research, 119 (14). pp. 2385-2386.

PDF (Published Version) - Published Version Restricted to Repository staff only

 

2

Abstract

[Extract] Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce reabsorption of glucose in the proximal tubule of the kidney, causing glycosuria and reducing blood glucose.1 Randomized controlled trials have shown that SGLT2 inhibitors reduce heart failure-related hospital admissions and cardiovascular death in a variety of populations, including people with heart failure, type 2 diabetes, and chronic kidney disease.2 SGLT2 inhibitors were originally developed as treatments to lower blood glucose, but their mechanism of action in terms of achieving reduction in cardiac events has been controversial.1 Animal studies have suggested beneficial effects of SGLT2 inhibitors on cardiac microvascular function and contractility, and that they reduce cardiac inflammation.

Actions (Repository Staff Only)

Item Control Page